Inspire Medical Systems, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Inspire Medical Systems, Inc. (NYSE: INSP) develops and commercializes the Inspire therapy, an implantable neurostimulation system designed to treat moderate to severe obstructive sleep apnea (OSA) in adult patients unable to use or get consistent benefit from continuous positive airway pressure (CPAP) devices. The company's core products and services include the Inspire Upper Airway Stimulation (UAS) system, consisting of the Inspire implantable pulse generator (IPG), stimulation lead, sensing lead, and external patient remote control; surgical tools and accessories for implantation; the myInspire patient management platform for remote monitoring and therapy adjustments; and physician and patient education programs supporting therapy adoption. Inspire therapy offers a masked volume reduction alternative to CPAP, with implantation performed by ENTs and sleep surgeons in outpatient procedures; the company provides direct-to-consumer marketing, reimbursement support services, and post-market clinical research through its registry studies. Founded in 2007 and headquartered in Golden Valley, Minnesota, Inspire Medical Systems operates primarily in the United States, with expanding commercial presence in Europe (including select countries via partnerships) and international markets targeting adult OSA patients underserved by traditional therapies. The company serves sleep clinics, ENT practices, hospitals, and sleep surgeons as key customers, focusing on the medical device segment of the sleep health industry valued at billions annually. In recent developments, Inspire Medical Systems reported strong revenue growth in 2025, driven by increased procedure volumes and market adoption; the company expanded its European operations through new regulatory approvals and partnerships in 2024-2025. It launched enhancements to the Inspire therapy platform, including software updates for improved therapy titration and remote monitoring capabilities; additionally, Inspire announced positive results from ongoing post-market studies demonstrating long-term efficacy and safety, supporting expanded indications. No major acquisitions, funding rounds, or name changes were reported in the last 1-2 years, with strategic focus remaining on U.S. market penetration and international scaling.
Company News
Why Is Inspire (INSP) Down 4.1% Since Last Earnings Report?
Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
ADAR1 Capital Management LLC Takes Position in Inspire Medical Systems, Inc. $INSP
Bank of America Corp DE Trims Stock Holdings in Inspire Medical Systems, Inc. $INSP
Deutsche Bank AG Makes New $7.86 Million Investment in Inspire Medical Systems, Inc. $INSP
INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue?
Here's Why You Should Add INSP Stock to Your Portfolio Now
Contrasting Medacta Group (OTCMKTS:MEDGF) & Inspire Medical Systems (NYSE:INSP)
New Strong Buy Stocks for August 18th
Assenagon Asset Management S.A. Increases Holdings in Inspire Medical Systems, Inc. $INSP
Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?
INSP Raises 2026 Outlook as Reimbursement Headwinds Start to Ease
INSP's 28.1% Past-Month Rally Raises a Key Question for Investors
Amundi Sells 107,792 Shares of Inspire Medical Systems, Inc. $INSP
Inspire Medical Q2 Earnings Beat Estimates, '26 View Raised, Stock Up
Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results
Inspire Medical Systems, Inc. (INSP) Q2 2026 Earnings Call Transcript
Inspire Medical Systems Q2 Earnings Call Highlights
Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics
Inspire Medical Systems (INSP) Q2 Earnings and Revenues Beat Estimates